Beckman Coulter's 4th Quarter and Full Year 2007 Revenue Grows 10.8% and 9.2%, Respectively; 2007 Earnings Per Share Be... (or molecular diagnostics. The acquisitio...)

HOME >> MEDICINE >> NEWS

Beckman Coulter's 4th Quarter and Full Year 2007 Revenue Grows 10.8% and 9.2%, Respectively; 2007 Earnings Per Share Beat Outlook

Date:2/8/2008

or molecular diagnostics. The acquisition of the Dako flow cytometry business and the acquired portfolio of technology from NexGen provide significant new capability in the high-value arenas of Immunoassay, Molecular Diagnostics and Flow Cytometry.

"Strength in clinical systems, assay development, work cell solutions and automation will continue to identify Beckman Coulter as a leader in the clinical diagnostics market, while our continued investment in new technologies and emerging markets create a pathway to sustain above market growth well into the next decade. We are focused on creating shareholder value through growth, quality and operating excellence. Through our comprehensive approach to simplifying, automating and innovating laboratory processes, we are dedicated to improving patient health and reducing the cost of care," Garrett said.

Investor Conference Call

As previously announced, there will be a conference call today, Friday, February 8, 2008 at 8:30 am ET to discuss the fourth quarter and full year ended December 31, 2007 results. The call will also be webcast live. The call is accessible to all investors through Beckman Coulter's website at http://www.beckmancoulter.com or at http://www.streetevents.com. When accessing the webcast through the Beckman Coulter site, select "go to IR" under Investor Relations and find the call listed under "What's Ahead". The webcast will be archived on both websites for future on-demand replay through Friday, February 22, 2008.

About Beckman Coulter

Beckman Coulter, Inc., based in Fullerton, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of
'/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Related medicine news :

1. Beckman Coulter Announces Licensing Option Agreements for Cancer Genes with Johns Hopkins University
2. Beckman Coulter Signs Agreements With Amerinet, Inc.; Ten-Year Partnership Extended for Another Three Years
3. Beckman Coulter to Present at the Credit Suisse Global Healthcare Conference
4. Beckman Coulter to Acquire Flow Cytometry Instrumentation Business From Dako
5. Beckman Coulter to Present at the 2007 RBC Capital Markets Healthcare Conference
6. Haemacure Reports Third Quarter 2007 Results
7. Weight Watchers Declares Quarterly Dividend
8. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
9. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
10. Medical Services International Maintains Pace in Second Quarter
11. Martek Announces Third Quarter 2007 Financial Results

Post Your Comments:

(Date:3/18/2010)... Taxes, Other Tobacco Prevention Initiatives , ... , , ... ... ... WASHINGTON , March 18 Kids in New Jersey will take center stage in the fight against tobacco on March ...

(Date:3/18/2010)... ... , , ... ... ... New Hampshire will take center stage in the fight against tobacco on March 24 as they join thousands of young people nationwide ...

(Date:3/18/2010)... President and CEO, Legacy(SM) , ... , , ... ... WASHINGTON , March ... ...

(Date:3/18/2010)... of U.S. medical students choosing internal medicine residencies ... significantly impact the shortage of primary care physicians. ... Program report, 2,722 U.S. seniors at medical schools ... 3.4 percent increase from 2,632 in 2009. The ... (2,660), 2007 (2,680), and 2006 (2,668). In comparison, ...

(Date:3/18/2010)... In its 21-year history, under the ... leaders, SRLA has trained more than 40,000 teenagers from ... area to complete the 26.2 mile Los Angeles Marathon. ... volunteer leaders will again participate in the LA Marathon. ... SRLA,s mission is to challenge at-risk secondary students to ...

Breaking Medicine News(10 mins):Health News:New Jersey Kids 'Kick Butts' on March 24 2 Health News:New Jersey Kids 'Kick Butts' on March 24 3 Health News:New Jersey Kids 'Kick Butts' on March 24 4 Health News:New Jersey Kids 'Kick Butts' on March 24 5 Health News:New Hampshire Kids 'Kick Butts' on March 24 2 Health News:New Hampshire Kids 'Kick Butts' on March 24 3 Health News:New Hampshire Kids 'Kick Butts' on March 24 4 Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 2 Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 3 Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 4 Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 5 Health News:Residency match results not encouraging for adults needing primary care 2 Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 2 Health News:Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years 3

[0] New Jersey Kids 'Kick Butts' on March 24 [0] New Hampshire Kids 'Kick Butts' on March 24 [0] Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco [0] Residency match results not encouraging for adults needing primary care [0] Students Run LA Takes 40,000 Students Across the Marathon Finish Line Over Past 21 Years

... of colon cancer is the formation of benign tumours, ... may progress to produce colon cancer if they undergo ... IRB Barcelona under the direction of Eduard Batlle, ICREA ... discovered a new mechanism by which the benign tumour ...

... AIDS Research Center at Massachusetts General Hospital (PARC-MGH) may ... off the immune systems response against HIV. Last ... called PD-1 that suppresses the activity of HIV-specific CD8 ... the researchers describe how a regulatory protein called CTLA-4 ...

... experts , , SUNDAY, Sept. 30 (HealthDay News) -- Black ... visit emergency rooms or be hospitalized for the condition ... a new study that reaches the controversial conclusion that ... racial disparities." , However, that genetics theory was quickly ...

... to Create Sustainable Breast Cancer Programs in ... Countries with Highest Potential, Greatest Need, BUDAPEST, Hungary, ... receiving a breast cancer diagnosis each year, it has ... about this,life-threatening disease. Building on the U.S.-Middle East Partnership ...

... is the daily,"Profile America" feature from the U.S. Census ... is a time to promote,both fun and good health ... will see locally organized events at hundreds of locations ... involvement, one of the,goals of the U.S. Surgeon General,s ...

... for hope, experts say , , FRIDAY, Sept. 28 (HealthDay ... treat the autoimmune disease lupus is building up steam, ... upbeat tone, researchers from across the United States spoke ... Institute (LRI) of the improving outlook for patients with ...

Other Medicine News:Health News:Researchers at IRB Barcelona discover one of the mechanisms that prevents the spread of colon cancer 2 Health News:Second pathway behind HIV-associated immune system dysfunction identified 2 Health News:Do Blacks Have Genetic Weakness to Asthma? 2 Health News:Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries 2 Health News:Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries 3 Health News:Better Lupus Treatments on the Horizon 2 Health News:Better Lupus Treatments on the Horizon 3 Health News:Better Lupus Treatments on the Horizon 4

Researchers at IRB Barcelona discover one of the mechanisms that prevents the spread of colon cancer Second pathway behind HIV-associated immune system dysfunction identified Do Blacks Have Genetic Weakness to Asthma?Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries U.S. Census Bureau Daily Feature for September 29 Better Lupus Treatments on the Horizon

(Date:3/18/2010)... March 18 Poniard Pharmaceuticals, Inc. ... innovative oncology therapies, today announced that the U.S. Patent ... the composition of matter patent for picoplatin as RE41209, ... 2010 . The reissue was applied for May ... , the USPTO released the "Issue Notification" for the ...

(Date:3/18/2010)... , March 18 ... Chief Executive Officer, Pfizer, was elected board ... of America (PhRMA) today at the trade ... Chief Executive Officer Christopher Viehbacher ... Directors, and John C. Lechleiter , ...

(Date:3/18/2010)... results in too much ammonia in the blood. , ... , , ... ... (Logo: ... ...

Breaking Medicine Technology:U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 2 U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 3 U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 4 U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter 5 Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 2 Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 3 Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 4 Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 5 Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 6 Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 7 Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts 8 FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 2 FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 3 FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 4 FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels 5 Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 1 Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 2 Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 3 Exposure to lead tobacco smoke raises risk of ADHD 10856 1 Exposure to lead tobacco smoke raises risk of ADHD 10856 2 Measuring and modeling blood flow in malaria 61892 1 Measuring and modeling blood flow in malaria 61892 2

[0] U.S. Patent and Trademark Office Grants Reissue Patent on Picoplatin Composition of Matter [0] Pfizer's Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts [0] FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels

... also showed differences in gastrointestinal and lipid effects ... study population, PRINCETON, N.J., Feb. 6 ... results from the CASTLE study, in which,300 mg ... mg of,ritonavir (REYATAZ/r) showed similar antiviral efficacy to ...

... Offers Hope for Treatment of,Children, WHITE PLAINS, N.Y., ... a rare craniofacial birth defect in,mice and holds promise ... research funded in part by the March of Dimes., ... journal Nature Medicine,demonstrates the potential for translating basic research ...

Other Medicine Technology:CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 2 CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 3 CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 4 CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 5 CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 6 Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice 2

CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice

Permits rotation of the globe during examination. Overall length,123mm....

... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...

... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...

Medicine Products:

Uretts-Zavalia Depressor & Fixation Pick (For rotating globe)Schepens Depressor 8.0mm Wide Tip Thimble Size 12 Schepens Depressor 8.0mm Wide Tip Thimble Size 8 Hardten Collector Sponge

Beckman Coulter's 4th Quarter and Full Year 2007 Revenue Grows 10.8% and 9.2%, Respectively; 2007 Earnings Per Share Be...(or molecular diagnostics. The acquisitio...),Health